This article is more than 5 years old. Information may no longer be current.
VIDEO: LATITUDE–TIMI 60 results raise ‘intriguing questions’ regarding anti-inflammatory drugs, CV event reduction
CHICAGO — Michelle L. O’Donoghue, MD, MPH, cardiologist and investigator with the TIMI Study Group, cardiovascular division, Brigham and Women’s Hospital, reviews results from the LATITUDE–TIMI 60 trial, looking at the p38 mitogen-activated protein kinase inhibitor losmapimod to treat patients with acute MI.
She offers background on losmapimod (GlaxoSmithKline), citing reasons for the hoped-for myocardial protection, and details the study from patient population through design and methods to outcomes.
“Losmapimod significantly reduced C-reactive protein concentration at serial time points … and NT-ProBNP concentration,” O’Donoghue said. “However, when we looked at the primary outcome … losmapimod did not reduce the risk of CV events.”
She outlines several “interesting challenges” as research moved ahead — from reconsidering of surrogate endpoints to exploring specific patient populations to investigating the potential of other anti-inflammatory drugs.